Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study
Dana-Farber Cancer Institute · with National Institute on Aging (NIA) · NCT07123649
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 80+ · Women only
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 2
- Target enrollment
- 364
- US sites recruiting
- 1
- Study start
- September 11, 2025
- Record last updated
- April 22, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study evaluates the effectiveness of a Shared Decision-Making (SDM) toolkit designed to support older breast cancer survivors aged 80 and above in making informed decisions about continuing surveillance mammography.
Being studied: Shared Decision-Making Toolkit
Conditions: Breast Cancer
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Participant Inclusion Criteria
- Women aged ≥ 80 years at the time of registration
- History of stage 0-III breast cancer (Of note: ductal carcinoma in situ [DCIS], pleomorphic lobular carcinoma in situ [because it is typically treated like DCIS], or invasive breast cancer of any subtype are all eligible)
- No history of a recurrent breast cancer (i.e., a breast cancer that is deemed metastatic or a locoregional recurrence of a prior cancer per clinician judgement rather than a new primary breast cancer). If a person has been diagnosed with multiple distinct breast cancers over time (e.g., history of left and right breast cancer), they are eligible as long as they meet other requirements for time since surgery, etc.
- Has at least one intact breast
- Has had mammogram screening/surveillance within the last 24 months
-≥ 12 months since most recent breast surgery to affected breast (e.g., breast reduction surgery on an unaffected breast within 12 months is ok)
- No active cancer-directed therapy other than hormonal therapy and/or CDK 4/6 inhibitor therapy
- Ability and willingness to take surveys
- Receiving at least some of their oncology follow-up care at a participating site
- Most recent mammogram report for the potential participant did not recommend additional diagnostic work-up or close interval follow-up imaging
- If a patient required diagnostic breast testing in the past or at the time of the most recent mammogram AND the results were resolved to benign findings with no additional diagnostics recommended, they are eligible.
- If a patient's most recent mammogram result isn't yet available at the time of approach or study consent, the patient is eligible to proceed with consent and enrollment. If this mammogram then abnormal or requires additional imaging, that patient will not be included in the study analyses or surveys. This patient will be replaced.
Participant Exclusion Criteria
- Inability to provide informed consent
- Assigned male sex at birth
- Breast or recent imaging findings requiring diagnostic testing at baseline
- Prior discontinuation of mammography by electronic medical record (EMR) review or patient report
- Prior atypical ductal hyperplasia (ADH) or non-pleomorphic LCIS only
- Psychiatric illness situations that would limit compliance with study requirements
- Those with metastatic breast cancer
- Those in hospice care
- Those whose clinician is not willing to participate
- Pregnant women, young patients, and those in prison will not be eligible for enrollment given the study design and aims supporting study in a different population focused on older adults
Clinician Inclusion Criteria
- Must be an active clinician (MD, NP, or PA) at a participating institution
- Sees at least one breast-cancer survivor aged ≥ 80
- Clinician must be able to read, speak, and write in English
Recruiting US locations
Dana-Farber Cancer Institute
Boston, MA 02115
Site contact: Rachel Freedman, MD, MPH · 617-632-4587 · Rachel_freedman@dfci.harvard.edu
Study contacts (from the official record)
- Rachel Freedman, MD, MPH · 617-632-4587 · Rachel_freedman@dfci.harvard.edu
Similar studies in Massachusetts
All healthy volunteers studies in Massachusetts →- RecruitingHealthy volunteersPhase 1/Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
Mabylon AG
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Haya Therapeutics, Inc.
- Location
- Boston, MA + 1 other US site
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Boston, MA + 49 other US sites
- Eligibility basics
- Ages 60+